Top

Published in:

01-05-2015 | Clinical Study

Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas

Authors: Asim K. Bag, Hyunki Kim, Yi Gao, Mark Bolding, Paula P. Warren, Hassan M. Fathallah-Shaykh, Demet Gurler, James M. Markert, John Fiveash, Timothy M. Beasley, Ayaz Khawaja, Gregory K. Friedman, Philip R. Chapman, Louis B. Nabors, Xiaosi Han

Published in: Journal of Neuro-Oncology | Issue 3/2015

Abstract

Bevacizumab is widely used for treatment of high-grade gliomas and other malignancies. Because bevacizumab has been shown to be associated with neurocognitive decline, this study is designed to investigate whether prolonged treatment with bevacizumab is also associated with brain atrophy. We identified 12 high-grade glioma patients who received bevacizumab for 12 months at the first recurrence and 13 matched controls and blindly compared the volumes of the contralateral hemispheres and contralateral ventricle in these two groups at baseline and after 12 ± 2 months of the baseline scan by two independent analyses. The volumes of the contralateral hemispheres and ventricles did not differ significantly between the two groups at baseline. Whereas, in the control group the volumes of the contralateral hemisphere changed subtly from baseline to follow-up (p = 0.23), in the bevacizumab-treated group the volumes significantly decreased from baseline to follow-up (p = 0.03). There was significant increase in the contralateral ventricle volume from base line to follow-up scans in both the control group (p = 0.01) and in the bevacizumab group (p = 0.005). Both the absolute and the percentage changes of contralateral hemisphere volumes and contralateral ventricular volumes between the two patient groups were statistically significant (p < 0.05). Results of this study demonstrate prolonged treatment with bevacizumab is associated with atrophy of the contralateral brain hemisphere.

Available only for authorised users

Maharaj AS, Saint-Geniez M, Maldonado AE, D’Amore PA (2006) Vascular endothelial growth factor localization in the adult. Am J Pathol 168:639–648CrossRefPubMedCentralPubMed

Licht T, Eavri R, Goshen I, Shlomai Y, Mizrahi A, Keshet E (2010) VEGF is required for dendritogenesis of newly born olfactory bulb interneurons. Development 137:261–271. doi:10.1242/dev.039636 CrossRefPubMed

Licht T, Goshen I, Avital A, Kreisel T, Zubedat S, Eavri R, Segal M, Yirmiya R, Keshet E (2011) Reversible modulations of neuronal plasticity by VEGF. Proc Natl Acad Sci U S A 108:5081–5086. doi:10.1073/pnas.1007640108 CrossRefPubMedCentralPubMed

Bengoetxea H, Argandona EG, Lafuente JV (2008) Effects of visual experience on vascular endothelial growth factor expression during the postnatal development of the rat visual cortex. Cereb Cortex 18:1630–1639CrossRefPubMedCentralPubMed

Acker T, Beck H, Plate KH (2001) Cell type specific expression of vascular endothelial growth factor and angiopoietin-1 and -2 suggests an important role of astrocytes in cerebellar vascularization. Mech Dev 108:45–57CrossRefPubMed

Barouk S, Hintz T, Li P, Duffy AM, MacLusky NJ, Scharfman HE (2011) 17beta-estradiol increases astrocytic vascular endothelial growth factor (VEGF) in adult female rat hippocampus. Endocrinology 152:1745–1751. doi:10.1210/en.2010-1290 CrossRefPubMedCentralPubMed

Weidemann A, Kerdiles YM, Knaup KX, Rafie CA, Boutin AT, Stockmann C, Takeda N, Scadeng M, Shih AY, Haase VH, Simon MC, Kleinfeld D, Johnson RS (2009) The glial cell response is an essential component of hypoxia-induced erythropoiesis in mice. J Clin Investig 119:3373–3383. doi:10.1172/JCI39378 PubMedCentralPubMed

Licht T, Keshet E (2013) Delineating multiple functions of VEGF-A in the adult brain. Cell Mol Life Sci 70:1727–1737. doi:10.1007/s00018-013-1280-x CrossRefPubMed

Cao L, Jiao X, Zuzga DS, Liu Y, Fong DM, Young D, During MJ (2004) VEGF links hippocampal activity with neurogenesis, learning and memory. Nat Genet 36:827–835CrossRefPubMed

10.

Jin K, Zhu Y, Sun Y, Mao XO, Xie L, Greenberg DA (2002) Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci U S A 99:11946–11950CrossRefPubMedCentralPubMed

11.

Schanzer A, Wachs FP, Wilhelm D, Acker T, Cooper-Kuhn C, Beck H, Winkler J, Aigner L, Plate KH, Kuhn HG (2004) Direct stimulation of adult neural stem cells in vitro and neurogenesis in vivo by vascular endothelial growth factor. Brain Pathol 14:237–248CrossRefPubMed

12.

Gao P, Shen F, Gabriel RA, Law D, Yang E, Yang GY, Young WL, Su H (2009) Attenuation of brain response to vascular endothelial growth factor-mediated angiogenesis and neurogenesis in aged mice. Stroke 40:3596–3600. doi:10.1161/STROKEAHA.109.561050 CrossRefPubMedCentralPubMed

13.

Louissaint A Jr, Rao S, Leventhal C, Goldman SA (2002) Coordinated interaction of neurogenesis and angiogenesis in the adult songbird brain. Neuron 34:945–960CrossRefPubMed

14.

Wang Y, Jin K, Mao XO, Xie L, Banwait S, Marti HH, Greenberg DA (2007) VEGF-overexpressing transgenic mice show enhanced post-ischemic neurogenesis and neuromigration. J Neurosci Res 85:740–747CrossRefPubMed

15.

Adamcio B, Sperling S, Hagemeyer N, Walkinshaw G, Ehrenreich H (2010) Hypoxia inducible factor stabilization leads to lasting improvement of hippocampal memory in healthy mice. Behav Brain Res 208:80–84. doi:10.1016/j.bbr.2009.11.010 CrossRefPubMed

16.

Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676CrossRefPubMed

17.

Sundberg C, Nagy JA, Brown LF, Feng D, Eckelhoefer IA, Manseau EJ, Dvorak AM, Dvorak HF (2001) Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. Am J Pathol 158:1145–1160CrossRefPubMedCentralPubMed

18.

van Bruggen N, Thibodeaux H, Palmer JT, Lee WP, Fu L, Cairns B, Tumas D, Gerlai R, Williams SP, van Lookeren Campagne M, Ferrara N (1999) VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J Clin Investig 104:1613–1620CrossRefPubMedCentralPubMed

19.

Salmaggi A, Eoli M, Frigerio S, Silvani A, Gelati M, Corsini E, Broggi G, Boiardi A (2003) Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol 62:297–303CrossRefPubMed

20.

Schmidt NO, Westphal M, Hagel C, Ergun S, Stavrou D, Rosen EM, Lamszus K (1999) Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 84:10–18CrossRefPubMed

21.

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740. doi:10.1200/JCO.2008.19.8721 CrossRefPubMed

22.

Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740–745. doi:10.1200/JCO.2008.16.3055 CrossRefPubMedCentralPubMed

23.

Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, Isachenko N, Fouse SD, Phillips JJ, Cheresh DA, Park M, Bergers G (2012) VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22:21–35. doi:10.1016/j.ccr.2012.05.037 CrossRefPubMedCentralPubMed

24.

Soda Y, Myskiw C, Rommel A, Verma IM (2013) Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme. J Mol Med 91:439–448. doi:10.1007/s00109-013-1019-z CrossRefPubMedCentralPubMed

25.

Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Eng J Med 370:699–708. doi:10.1056/NEJMoa1308573 CrossRef

26.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med 352:987–996. doi:10.1056/NEJMoa043330 CrossRef

27.

Kleihues PBP, Aldape Kd et al (2007) WHO classification of tumors of the central nervous system. IARC Press, Lyon

28.

Bag AK, Cezayirli PC, Davenport JJ, Gaddikeri S, Fathallah-Shaykh HM, Cantor A, Han XS, Nabors LB (2014) Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters. J Neurooncol 120:361–370. doi:10.1007/s11060-014-1560-9 CrossRefPubMed

29.

Linkous AG, Yazlovitskaya EM (2011) Angiogenesis in glioblastoma multiforme: navigating the maze. Anticancer Agents Med Chem 11:712–718CrossRefPubMed

30.

Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8:610–622CrossRefPubMed

31.

Knizetova P, Ehrmann J, Hlobilkova A, Vancova I, Kalita O, Kolar Z, Bartek J (2008) Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay. Cell Cycle 7:2553–2561CrossRefPubMed

32.

Hoelzinger DB, Demuth T, Berens ME (2007) Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J Natl Cancer Inst 99:1583–1593CrossRefPubMed

33.

Welti J, Loges S, Dimmeler S, Carmeliet P (2013) Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Ivestig 123:3190–3200. doi:10.1172/JCI70212 CrossRef

34.

Goel HL, Mercurio AM (2013) VEGF targets the tumour cell. Nat Rev Cancer 13:871–882. doi:10.1038/nrc3627 CrossRefPubMedCentralPubMed

35.

Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Eng J Med 370:709–722. doi:10.1056/NEJMoa1308345 CrossRef

36.

Duning T, Kloska S, Steinstrater O, Kugel H, Heindel W, Knecht S (2005) Dehydration confounds the assessment of brain atrophy. Neurology 64:548–550. doi:10.1212/01.WNL.0000150542.16969.CC CrossRefPubMed

37.

Rao AB, Richert N, Howard T, Lewis BK, Bash CN, McFarland HF, Frank JA (2002) Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b. Neurology 59:688–694CrossRefPubMed

38.

Li SF, Sun YB, Meng QH, Li SR, Yao WC, Hu GJ, Li ZJ, Wang RZ (2009) Recombinant adeno-associated virus serotype 1-vascular endothelial growth factor promotes neurogenesis and neuromigration in the subventricular zone and rescues neuronal function in ischemic rats. Neurosurgery 65:771–779. doi:10.1227/01.NEU.0000349931.61771.52 CrossRefPubMed

39.

Kim BW, Choi M, Kim YS, Park H, Lee HR, Yun CO, Kim EJ, Choi JS, Kim S, Rhim H, Kaang BK, Son H (2008) Vascular endothelial growth factor (VEGF) signaling regulates hippocampal neurons by elevation of intracellular calcium and activation of calcium/calmodulin protein kinase II and mammalian target of rapamycin. Cell Signal 20:714–725. doi:10.1016/j.cellsig.2007.12.009 CrossRefPubMed

40.

Ruiz de Almodovar C, Coulon C, Salin PA, Knevels E, Chounlamountri N, Poesen K, Hermans K, Lambrechts D, Van Geyte K, Dhondt J, Dresselaers T, Renaud J, Aragones J, Zacchigna S, Geudens I, Gall D, Stroobants S, Mutin M, Dassonville K, Storkebaum E, Jordan BF, Eriksson U, Moons L, D’Hooge R, Haigh JJ, Belin MF, Schiffmann S, Van Hecke P, Gallez B, Vinckier S, Chedotal A, Honnorat J, Thomasset N, Carmeliet P, Meissirel C (2010) Matrix-binding vascular endothelial growth factor (VEGF) isoforms guide granule cell migration in the cerebellum via VEGF receptor Flk1. J Neurosci 30:15052–15066. doi:10.1523/JNEUROSCI.0477-10.2010 CrossRefPubMed

Title: Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas
Authors: Asim K. Bag
Hyunki Kim
Yi Gao
Mark Bolding
Paula P. Warren
Hassan M. Fathallah-Shaykh
Demet Gurler
James M. Markert
John Fiveash
Timothy M. Beasley
Ayaz Khawaja
Gregory K. Friedman
Philip R. Chapman
Louis B. Nabors
Xiaosi Han
Publication date: 01-05-2015
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2015
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-015-1751-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2015

MiR-137 inhibits proliferation and angiogenesis of human glioblastoma cells by targeting EZH2

MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab

Clinical characteristics and surgical outcomes of primary spinal paragangliomas

Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices

Evaluation of absolute and normalized apparent diffusion coefficient (ADC) values within the post-operative T2/FLAIR volume as adverse prognostic indicators in glioblastoma

Prediction of anaplastic transformation in low-grade oligodendrogliomas based on magnetic resonance spectroscopy and 1p/19q codeletion status